Sugi Predict

Sugi Predict / Compounds / SCHEMBL4539236

SCHEMBL4539236

SCHEMBL4539236

COc1c(Br)ccc2cccnc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 7/20 0.52
▸ KDM4E B2RXH2 4/20 0.52
▸ MAPT P10636 4/20 0.52
▸ SMN1; SMN2 Q16637 3/20 0.52
▸ CCR1 P32246 3/20 0.52
▸ CCR5 P51681 3/20 0.52
▸ CCR8 P51685 3/20 0.52
▸ CYP3A4 P08684 2/20 0.52
▸ GMNN O75496 1/20 0.52
▸ TP53 P04637 1/20 0.52
▸ HSP90AA1 P07900 1/20 0.52
▸ MMP2 P08253 1/20 0.52
▸ CYP2D6 P10635 1/20 0.52
▸ MMP9 P14780 1/20 0.52
▸ ALOX15 P16050 1/20 0.52
▸ TSHR P16473 1/20 0.52
▸ NFKB1 P19838 1/20 0.52
▸ MMP8 P22894 1/20 0.52
▸ THPO P40225 1/20 0.52
▸ MTOR P42345 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18319498 0.83 LMNA (0.50) LMNAKDM4EMAPTSMN1; SMN2CCR1
SCHEMBL14768504 0.80 LMNA (0.59) LMNAKDM4EMAPTSMN1; SMN2CCR1
SCHEMBL18318478 0.79 LMNA (0.44) LMNAKDM4EMAPTSMN1; SMN2CCR1
SCHEMBL10087924 0.79 LMNA (0.53) LMNAKDM4EMAPTSMN1; SMN2CCR1
SCHEMBL4700675 0.79 LMNA (0.52) LMNAKDM4EMAPTSMN1; SMN2CCR1
SCHEMBL6480924 0.78 MAPT (0.48) LMNAKDM4EMAPTSMN1; SMN2CCR1
SCHEMBL620812 0.77 KDM4E (0.57) LMNAKDM4EMAPTSMN1; SMN2TP53
SCHEMBL25184887 0.76 LMNA (0.48) LMNAKDM4EMAPTSMN1; SMN2CCR1
SCHEMBL29953507 0.76 LMNA (0.48) LMNAKDM4EMAPTSMN1; SMN2CCR1
SCHEMBL21657686 0.76 LMNA (0.48) LMNAKDM4EMAPTSMN1; SMN2CCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260083721-A1 7-CYANO-8-HYDROXYQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF JIANGSU YAHONG MEDITECH CO LTD (CN) 2026-03-26 — — US disclosed
US-12448392-B2 Spiropiperidine derivatives CEPHALON LLC (US) 2025-10-21 — — US disclosed
US-12441702-B2 Substituted 4-benzyl and 4-benzoyl piperidine derivates CEPHALON LLC (US) 2025-10-14 — — US disclosed
EP-4623914-A1 USE OF 8-HYDROXYQUINOLINE DERIVATIVE Jiangsu Yahong Meditech Co., Ltd. (CN) 2025-10-01 — — EP disclosed
CN-120035438-A Use of 8-hydroxyquinoline derivatives 江苏亚虹医药科技股份有限公司 2025-05-23 — — CN disclosed
EP-4534530-A1 7-CYANO-8-HYDROXYQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF Jiangsu Yahong Meditech Co., Ltd. (CN) 2025-04-09 — — EP disclosed
CN-118679149-A 7-Cyano-8-hydroxyquinoline derivative, preparation method and medical application thereof 江苏亚虹医药科技股份有限公司 2024-09-20 — — CN disclosed
WO-2024109684-A1 USE OF 8-HYDROXYQUINOLINE DERIVATIVE 江苏亚虹医药科技股份有限公司 2024-05-30 — — WO disclosed
CN-118059101-A Use of 8-hydroxyquinoline derivatives 江苏亚虹医药科技股份有限公司 2024-05-24 — — CN disclosed
US-20240166625-A1 Substituted 4-Benzyl And 4-Benzoyl Piperidine Derivates CEPHALON LLC 2024-05-23 — — US disclosed
EP-2744333-B1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2016-10-05 — — EP disclosed
US-9084794-B2 Fatty acid synthase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2015-07-21 — — US disclosed
US-20140194415-A1 FATTY ACID SYNTHASE INHIBITORS GlaxoSmithKline Intellectual Property (No2) Limite (GB) 2014-07-10 — — US disclosed
EP-2744333-A1 FATTY ACID SYNTHASE INHIBITORS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2014-06-25 — — EP disclosed
WO-2014008223-A2 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2014-01-09 — — WO disclosed
EP-2637660-A1 FATTY ACID SYNTHASE INHIBITORS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2013-09-18 — — EP disclosed
US-20130237535-A1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC 2013-09-12 — — US disclosed
WO-2013052716-A1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-04-11 — — WO disclosed
WO-2013028447-A1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-02-28 — — WO disclosed
WO-2012064642-A1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2012-05-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12441702-B2 Substituted 4-benzyl and 4-benzoyl piperidine derivates FASN, CES1, FADS2 LMNA 1531/4885KDM4E 536/4885MAPT 3856/4885
US-20240166625-A1 Substituted 4-Benzyl And 4-Benzoyl Piperidine Derivates FASN, CES1, FADS2 LMNA 1531/4885KDM4E 536/4885MAPT 3856/4885
US-20260083721-A1 7-CYANO-8-HYDROXYQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF HCCS, SLC38A7, HRAS LMNA 4494/4885KDM4E 3680/4885MAPT 4863/4885
US-20140194415-A1 FATTY ACID SYNTHASE INHIBITORS FASN, FADS2, FADS1 LMNA 1938/4885KDM4E 2143/4885MAPT 4695/4885
US-12448392-B2 Spiropiperidine derivatives FASN, FADS2, SCD5 LMNA 1331/4885KDM4E 3729/4885MAPT 4291/4885
US-20130237535-A1 FATTY ACID SYNTHASE INHIBITORS FASN, FADS1, FADS2 LMNA 2059/4885KDM4E 2007/4885MAPT 4498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.